| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANXA1 |
| Uniprot No | P04083 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 氨基酸序列 | MAMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAA LHKAIMVKGVDEATIIDILTKRNNAQRQQIKAAYLQETGKPLDETLKKAL TGHLEEVVLALLKTPAQFDADELRAAMKGLGTDEDTLIEILASRTNKEIR DINRVYREELKRDLAKDITSDTSGDFRNALLSLAKGDRSEDFGVNEDLAD SDARALYEAGERRKGTDVNVFNTILTTRSYPQLRRVFQKYTKYSKHDMNK VLDLELKGDIEKCLTAIVKCATSKPAFFAEKLHQAMKGVGTRHKALIRIM VSRSEIDMNDIKAFYQKMYGISLCQAILDETKGDYEKILVALCGGN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANXA1重组蛋白的3篇示例参考文献(注：文献为示例性概括，实际文献需通过学术数据库查询确认)：
---
1. **文献名称**: *"Recombinant ANXA1 suppresses neuroinflammation in murine models via FPR2-dependent signaling"*
**作者**: Lim LH, et al.
**摘要**: 研究证明重组ANXA1蛋白通过激活甲酰肽受体2(FPR2)显著抑制小胶质细胞炎症反应，减少促炎因子释放，为神经炎症疾病提供潜在治疗策略。
2. **文献名称**: *"Targeted delivery of recombinant ANXA1 protein inhibits breast cancer metastasis"*
**作者**: Chen Y, et al.
**摘要**: 利用纳米载体递送重组ANXA1蛋白，通过抑制NF-κB通路降低乳腺癌细胞侵袭性，并减少小鼠模型中肺转移病灶的形成。
3. **文献名称**: *"Structural and functional characterization of recombinant human ANXA1 in resolving acute inflammation"*
**作者**: Perretti M, et al.
**摘要**: 解析重组人ANXA1蛋白的结构，证实其N端肽段介导的抗炎作用，通过调控白细胞迁移和促进炎症消退，验证其在急性炎症模型中的治疗效果。
---
建议通过 **PubMed/Google Scholar** 搜索关键词 `recombinant ANXA1 protein` 或结合具体研究领域(如癌症、免疫)获取真实文献。
ANXA1 (Annexin A1) is a 37-kDa calcium- and phospholipid-binding protein belonging to the annexin superfamily. Initially identified as a glucocorticoid-regulated anti-inflammatory protein, it plays critical roles in modulating innate immune responses, cell proliferation, apoptosis, and membrane trafficking. Structurally, ANXA1 contains a conserved C-terminal core domain responsible for calcium-dependent membrane interactions and a unique N-terminal domain that mediates protein-protein interactions and post-translational modifications. Its biological activities include inhibiting phospholipase A2. regulating leukocyte migration, and resolving inflammation through formyl peptide receptor (FPR) signaling pathways.
Recombinant ANXA1 protein is produced using genetic engineering techniques, typically expressed in bacterial (e.g., E. coli) or mammalian expression systems to ensure proper folding and post-translational modifications. This engineered protein retains the functional epitopes of native ANXA1 while offering advantages such as high purity, batch-to-batch consistency, and reduced endotoxin levels. Researchers utilize recombinant ANXA1 to investigate its anti-inflammatory mechanisms, cancer progression (notably in breast and pancreatic cancers), and neurodegenerative diseases. It serves as a vital tool for studying protein-lipid interactions, developing therapeutic antibodies, and exploring ANXA1's dual role as both a tumor suppressor and promoter in different cellular contexts. Current applications extend to drug discovery targeting FPR receptors and inflammation-resolution therapies. The recombinant form's availability has significantly advanced understanding of ANXA1's pathophysiological roles while overcoming challenges associated with isolating the native protein from biological sources.
×
